Vibrio cholerae O1 classical biotype (V. cholerae O1 (CL))

Vibrio cholerae O1 classical biotype is a Gram-negative, comma-shaped bacterium that serves as the etiological agent of cholera, specifically identified as the primary cause of the first six global pandemics [7][11]. Unlike the currently dominant El Tor biotype, the classical biotype is characterized by its sensitivity to polymyxin B and bacteriophage IV, and it typically produces high levels of cholera toxin under specific environmental conditions [7][8][12]. The pathogen's primary mechanism of disease involves the colonization of the human small intestine via toxin-coregulated pili (TCP) and the subsequent secretion of cholera toxin, which induces a massive efflux of electrolytes and water into the intestinal lumen, leading to severe secretory diarrhea [8][10]. Therapeutic management of infections caused by this biotype focuses on rapid rehydration and the administration of antibiotics such as doxycycline, azithromycin, or tetracycline to reduce the bacterial load and shorten the duration of the illness [5][7]. Preventive measures include oral cholera vaccines (OCVs), such as the live-attenuated Vaxchora (CVD 103-HgR) and the inactivated Dukoral, which target the O1 surface antigens and the toxin B-subunit to elicit protective mucosal IgA and vibriocidal antibodies [1][2][4]. While modern outbreaks are predominantly caused by El Tor variants, the classical biotype remains a significant focus for vaccine development and epidemiological surveillance due to its high virulence and the necessity for cross-protective immunity [6][13].

Other names

Classical Vibrio choleraeV. cholerae O1 biotype classicalVibrio commaAsiatic cholera bacterium

Antibiotics target the bacterial ribosome (30S or 50S subunits) or DNA gyrase to inhibit growth and protein synthesis [5][7]. Vaccines target the bacterium's O1 surface antigens and cholera toxin B-subunit to induce protective mucosal immunity and prevent intestinal colonization [1][2].